OverviewSuggest Edit

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and be applied to a wide range of solid tumour types. In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 125,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
HQNottingham, GB


Oncimmune is headquartered in
Nottingham, United Kingdom

Location Map

Latest Updates

Employees (est.) (Sep 2019)57
Revenue (FY, 2018)£104 K(+30%)

Key People/Management at Oncimmune

Geoffrey Hamilton-Fairley

Geoffrey Hamilton-Fairley

Non-Executive Vice Chairman
Neal Navani

Neal Navani

Consultant Clinical Director
Andrea Murray

Andrea Murray

Chief Operational Scientist
Maarten Brusse

Maarten Brusse

Chief Commercial Officer, Asia Pacific
Show more

Oncimmune Office Locations

Oncimmune has offices in Nottingham and De Soto
Nottingham, GB (HQ)
Hucknall Rd
De Soto, US
8960 Commerce Dr
Show all (2)

Oncimmune Financials and Metrics

Summary Metrics

Founding Date


Oncimmune total Funding

$15 m

Oncimmune latest funding size

$15 m

Time since last funding

3 years ago

Oncimmune investors

Oncimmune's latest funding round in January 2017 was reported to be $15 m. In total, Oncimmune has raised $15 m
Show all financial metrics

Oncimmune Revenue

Oncimmune's revenue was reported to be £104 k in FY, 2018

Revenue (FY, 2018)


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBITDA (FY, 2018)


EBIT (FY, 2018)


Cash (31-May-2018)

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Revenue growth, %


Cost of goods sold


Gross profit

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income


Cash From Operating Activities


Cash From Financing Activities


Net Change in Cash

GBPY, 2018



Financial Leverage

-0.7 x
Show all financial metrics

Oncimmune Online and Social Media Presence

Embed Graph

Oncimmune Frequently Asked Questions

  • When was Oncimmune founded?

    Oncimmune was founded in 2006.

  • Who are Oncimmune key executives?

    Oncimmune's key executives are Geoffrey Hamilton-Fairley, Neal Navani and Andrea Murray.

  • How many employees does Oncimmune have?

    Oncimmune has 57 employees.

  • What is Oncimmune revenue?

    Latest Oncimmune annual revenue is £104 k.

  • What is Oncimmune revenue per employee?

    Latest Oncimmune revenue per employee is £1.8 k.

  • Who are Oncimmune competitors?

    Competitors of Oncimmune include PatientsLikeMe, Independa and Ingenious Med.

  • Where is Oncimmune headquarters?

    Oncimmune headquarters is located at Hucknall Rd, Nottingham.

  • Where are Oncimmune offices?

    Oncimmune has offices in Nottingham and De Soto.

  • How many offices does Oncimmune have?

    Oncimmune has 2 offices.